BRISTOL-MYERS SQUIBB CO (BMY) Stock Fundamental Analysis
NYSE:BMY • US1101221083
61.12 USD
+0.46 (+0.76%)
Last: Feb 23, 2026, 01:13 PM
We assign a fundamental rating of 6 out of 10 to BMY. BMY was compared to 192 industry peers in the Pharmaceuticals industry. While BMY has a great profitability rating, there are some minor concerns on its financial health. BMY is cheap, but on the other hand it scores bad on growth. BMY also has an excellent dividend rating. With these ratings, BMY could be worth investigating further for value and dividend investing!.
1. Profitability
1.1 Basic Checks
- In the past year BMY was profitable.
- In the past year BMY had a positive cash flow from operations.
- Of the past 5 years BMY 4 years were profitable.
- In the past 5 years BMY always reported a positive cash flow from operatings.
1.2 Ratios
- The Return On Assets of BMY (7.83%) is better than 89.06% of its industry peers.
- BMY has a Return On Equity of 38.19%. This is amongst the best in the industry. BMY outperforms 96.88% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 19.52%, BMY belongs to the top of the industry, outperforming 96.35% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for BMY is in line with the industry average of 12.95%.
- The last Return On Invested Capital (19.52%) for BMY is above the 3 year average (14.47%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.83% | ||
| ROE | 38.19% | ||
| ROIC | 19.52% |
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
1.3 Margins
- The Profit Margin of BMY (14.64%) is better than 86.46% of its industry peers.
- In the last couple of years the Profit Margin of BMY has grown nicely.
- Looking at the Operating Margin, with a value of 35.82%, BMY belongs to the top of the industry, outperforming 95.83% of the companies in the same industry.
- In the last couple of years the Operating Margin of BMY has grown nicely.
- BMY has a better Gross Margin (72.63%) than 80.73% of its industry peers.
- In the last couple of years the Gross Margin of BMY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.82% | ||
| PM (TTM) | 14.64% | ||
| GM | 72.63% |
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BMY is creating value.
- Compared to 1 year ago, BMY has more shares outstanding
- Compared to 5 years ago, BMY has less shares outstanding
- BMY has a better debt/assets ratio than last year.
2.2 Solvency
- BMY has an Altman-Z score of 2.55. This is not the best score and indicates that BMY is in the grey zone with still only limited risk for bankruptcy at the moment.
- BMY has a better Altman-Z score (2.55) than 66.67% of its industry peers.
- BMY has a debt to FCF ratio of 3.51. This is a good value and a sign of high solvency as BMY would need 3.51 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 3.51, BMY belongs to the top of the industry, outperforming 88.54% of the companies in the same industry.
- BMY has a Debt/Equity ratio of 2.33. This is a high value indicating a heavy dependency on external financing.
- With a Debt to Equity ratio value of 2.33, BMY is not doing good in the industry: 78.65% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.33 | ||
| Debt/FCF | 3.51 | ||
| Altman-Z | 2.55 |
ROIC/WACC2.24
WACC8.72%
2.3 Liquidity
- BMY has a Current Ratio of 1.26. This is a normal value and indicates that BMY is financially healthy and should not expect problems in meeting its short term obligations.
- BMY has a Current ratio of 1.26. This is in the lower half of the industry: BMY underperforms 77.08% of its industry peers.
- A Quick Ratio of 1.14 indicates that BMY should not have too much problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 1.14, BMY is doing worse than 74.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.14 |
3. Growth
3.1 Past
- BMY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 439.47%, which is quite impressive.
- Measured over the past years, BMY shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.92% on average per year.
- BMY shows a decrease in Revenue. In the last year, the revenue decreased by -0.22%.
- BMY shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.54% yearly.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
3.2 Future
- Based on estimates for the next years, BMY will show a decrease in Earnings Per Share. The EPS will decrease by -4.54% on average per year.
- BMY is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -5.62% yearly.
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-4.54%
Revenue Next Year-1.88%
Revenue Next 2Y-2.07%
Revenue Next 3Y-5.43%
Revenue Next 5Y-5.62%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 9.94, the valuation of BMY can be described as reasonable.
- 92.19% of the companies in the same industry are more expensive than BMY, based on the Price/Earnings ratio.
- BMY is valuated cheaply when we compare the Price/Earnings ratio to 26.99, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 10.04, which indicates a very decent valuation of BMY.
- Based on the Price/Forward Earnings ratio, BMY is valued cheaper than 88.54% of the companies in the same industry.
- BMY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.02.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.94 | ||
| Fwd PE | 10.04 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BMY is valued cheaply inside the industry as 93.23% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, BMY is valued cheaply inside the industry as 92.19% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.69 | ||
| EV/EBITDA | 7.39 |
4.3 Compensation for Growth
- BMY has an outstanding profitability rating, which may justify a higher PE ratio.
- BMY's earnings are expected to decrease with -3.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 4.18%, BMY is a good candidate for dividend investing.
- Compared to an average industry Dividend Yield of 1.07, BMY pays a better dividend. On top of this BMY pays more dividend than 96.88% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.81, BMY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.18% |
5.2 History
- The dividend of BMY is nicely growing with an annual growth rate of 6.51%!
- BMY has been paying a dividend for at least 10 years, so it has a reliable track record.
- BMY has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)6.51%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
- BMY pays out 71.52% of its income as dividend. This is not a sustainable payout ratio.
- BMY's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP71.52%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
NYSE:BMY (2/23/2026, 1:13:00 PM)
61.12
+0.46 (+0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05 2026-02-05/bmo
Earnings (Next)04-30 2026-04-30
Inst Owners81.87%
Inst Owner Change0.41%
Ins Owners0.02%
Ins Owner Change-1.12%
Market Cap124.43B
Revenue(TTM)48.19B
Net Income(TTM)7.05B
Analysts70.59
Price Target58.05 (-5.02%)
Short Float %1.47%
Short Ratio2.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.18% |
Yearly Dividend2.51
Dividend Growth(5Y)6.51%
DP71.52%
Div Incr Years3
Div Non Decr Years3
Ex-Date01-02 2026-01-02 (0.63)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.39%
Min EPS beat(2)6.92%
Max EPS beat(2)11.85%
EPS beat(4)4
Avg EPS beat(4)18.29%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.75%
EPS beat(12)11
Avg EPS beat(12)12.26%
EPS beat(16)15
Avg EPS beat(16)10.82%
Revenue beat(2)2
Avg Revenue beat(2)1.61%
Min Revenue beat(2)0.79%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)3.42%
Min Revenue beat(4)0.79%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.86%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)12
Avg Revenue beat(16)1.77%
PT rev (1m)2.01%
PT rev (3m)9.49%
EPS NQ rev (1m)1.98%
EPS NQ rev (3m)-3.3%
EPS NY rev (1m)0.24%
EPS NY rev (3m)-0.06%
Revenue NQ rev (1m)3.43%
Revenue NQ rev (3m)3.33%
Revenue NY rev (1m)6.84%
Revenue NY rev (3m)7.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.94 | ||
| Fwd PE | 10.04 | ||
| P/S | 2.58 | ||
| P/FCF | 9.69 | ||
| P/OCF | 8.79 | ||
| P/B | 6.74 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.39 |
EPS(TTM)6.15
EY10.06%
EPS(NY)6.09
Fwd EY9.96%
FCF(TTM)6.31
FCFY10.32%
OCF(TTM)6.95
OCFY11.38%
SpS23.67
BVpS9.07
TBVpS-11
PEG (NY)N/A
PEG (5Y)N/A
Graham Number35.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.83% | ||
| ROE | 38.19% | ||
| ROCE | 25.91% | ||
| ROIC | 19.52% | ||
| ROICexc | 23.22% | ||
| ROICexgc | 84.94% | ||
| OM | 35.82% | ||
| PM (TTM) | 14.64% | ||
| GM | 72.63% | ||
| FCFM | 26.65% |
ROA(3y)2.2%
ROA(5y)3.91%
ROE(3y)3.56%
ROE(5y)10.1%
ROIC(3y)14.47%
ROIC(5y)12.91%
ROICexc(3y)17.24%
ROICexc(5y)15.38%
ROICexgc(3y)72.12%
ROICexgc(5y)85.46%
ROCE(3y)19.19%
ROCE(5y)17.14%
ROICexgc growth 3Y-3.78%
ROICexgc growth 5Y13.73%
ROICexc growth 3Y21.19%
ROICexc growth 5Y33.96%
OM growth 3Y13.23%
OM growth 5Y20.59%
PM growth 3Y2.21%
PM growth 5YN/A
GM growth 3Y-2.43%
GM growth 5Y-0.33%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.33 | ||
| Debt/FCF | 3.51 | ||
| Debt/EBITDA | 2.03 | ||
| Cap/Depr | 32.69% | ||
| Cap/Sales | 2.72% | ||
| Interest Coverage | 8.22 | ||
| Cash Conversion | 66.54% | ||
| Profit Quality | 182.1% | ||
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 2.55 |
F-Score7
WACC8.72%
ROIC/WACC2.24
Cap/Depr(3y)19.36%
Cap/Depr(5y)15.61%
Cap/Sales(3y)2.66%
Cap/Sales(5y)2.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-4.54%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y1.45%
Revenue growth 5Y2.54%
Sales Q2Q%1.3%
Revenue Next Year-1.88%
Revenue Next 2Y-2.07%
Revenue Next 3Y-5.43%
Revenue Next 5Y-5.62%
EBIT growth 1Y49.54%
EBIT growth 3Y14.87%
EBIT growth 5Y23.65%
EBIT Next Year13.96%
EBIT Next 3Y0.03%
EBIT Next 5Y-1.73%
FCF growth 1Y-7.87%
FCF growth 3Y2.44%
FCF growth 5Y-0.69%
OCF growth 1Y-6.81%
OCF growth 3Y2.71%
OCF growth 5Y0.15%
BRISTOL-MYERS SQUIBB CO / BMY FAQ
What is the ChartMill fundamental rating of BRISTOL-MYERS SQUIBB CO (BMY) stock?
ChartMill assigns a fundamental rating of 6 / 10 to BMY.
What is the valuation status for BMY stock?
ChartMill assigns a valuation rating of 8 / 10 to BRISTOL-MYERS SQUIBB CO (BMY). This can be considered as Undervalued.
What is the profitability of BMY stock?
BRISTOL-MYERS SQUIBB CO (BMY) has a profitability rating of 9 / 10.
Can you provide the financial health for BMY stock?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BMY) is 5 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BMY) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BMY) is expected to decline by -1.05% in the next year.